2 JANUARY 2020

THERAPEUTIC PRODUCTS GUIDANCE

IMPORT AND SUPPLY OF AN UNREGISTERED THERAPEUTIC PRODUCT FOR PATIENTS’ USE

TPB-GN-004-002
REVISION HISTORY

Guidance Version
TPB-GN-004-002 (uploaded 2 January 2020)
TABLE OF CONTENTS

1. INTRODUCTION ............................................................................................................. 4

2. REQUIREMENTS FOR IMPORT AND SUPPLY OF UNREGISTERED THERAPEUTIC PRODUCTS FOR PATIENTS' USE ........................................................................ 4

   2.1 Importer’s and Wholesaler’s Licence ................................................................. 4

   2.2 Consignment Approval ..................................................................................... 5

   2.3 Labelling Requirements ..................................................................................... 7

   2.4 Requirement for Other Licences/Approval for Specific Products .......... 7

3. TRANSFER OF UNREGISTERED THERAPEUTIC PRODUCTS BETWEEN PHMCA-LICENSED HOSPITALS OR CLINICS .......................................................... 8

4. DUTIES AND OBLIGATIONS OF IMPORTERS, WHOLESALERS AND SUPPLIERS (INCLUDING HOSPITALS, CLINICS AND RETAIL PHARMACIES) .. 9

   4.1 Duties to Maintain Records of Receipt and Supply ........................................ 9

   4.2 Duties to Maintain Records of Defects and Adverse effects ..................... 10

   4.3 Duties to Report Defects and Serious Adverse Reactions ....................... 10

   4.4 Duties to Notify HSA Concerning Recall .................................................... 11

ANNEX A .......................................................................................................................... 12

ANNEX B .......................................................................................................................... 15
1. INTRODUCTION

This guidance outlines the special access route under regulation 5(1)(b)(i) and 51 of the Health Products (Therapeutic Products) Regulations for the import of an unregistered therapeutic product, as well as its subsequent supply under regulation 58(1)(f) and (g) of the Regulations.

These regulations serve to facilitate access to life-saving therapies where there is an unmet medical need, such as in situations where treatment option is absent and the patient’s health will be clinically compromised without treatment with the unregistered therapeutic product.

2. REQUIREMENTS FOR IMPORT AND SUPPLY OF UNREGISTERED THERAPEUTIC PRODUCTS FOR PATIENTS’ USE

Under the special access route, an unregistered therapeutic product may be imported by any of the following:

a) A licensed hospital or clinic¹ for use by a registered doctor or dentist practising at that hospital or clinic and for use in any patient under the care of that doctor or dentist;

b) A licensed retail pharmacy² acting on behalf of a registered doctor or dentist pursuant to a valid prescription; or

c) A company acting on behalf of a licensed hospital or clinic.

2.1 Importer’s and Wholesaler’s Licence

A company acting on behalf of a hospital or clinic is required to obtain a valid Therapeutic Products Importer’s Licence (TPIL) prior to carrying out any import

¹ Hospital or clinic licensed under the Private Hospitals and Medical Clinics Act (PHMCA) (Cap. 248)
² Retail pharmacy licensed under Health Products (Licensing of Retail Pharmacies) Regulations 2016
activity. The company must appoint one or more persons as a responsible person to be named in the TPIL, and the responsible person must be a qualified pharmacist\(^3\).

The company is also required to hold a valid Therapeutic Products Wholesaler’s Licence (TPWL) in order to supply the unregistered therapeutic product to the hospital or clinic.

A hospital or clinic importing an unregistered therapeutic product directly for use in a patient treated at that hospital or clinic is not required to hold TPIL. A retail pharmacy acting on behalf of a registered doctor or dentist may also import an unregistered therapeutic product that is intended for use a patient pursuant to a valid prescription without holding a TPIL.

In all cases, HSA’s prior approval must be obtained for each consignment of the unregistered therapeutic product to be imported (see section 2.2).

### 2.2 Consignment Approval

Pursuant to regulation 51(3) of the *Regulations*, HSA’s prior approval must be obtained for each consignment of the unregistered therapeutic product to be imported, and the amount imported must not exceed a total dosage of 3 months per patient based on the manufacturer’s recommended dosing regimen. Any application requesting for quantity exceeding the specified amount must be accompanied by substantive justification. The consignment approval is valid for 6 months from the date of approval.

The use of unregistered therapeutic products should only be reserved for situations where there is no alternative registered treatment available. **Clinicians are reminded to exercise discretion in their clinical decisions on using unregistered therapeutic products. These products are not evaluated by HSA for quality.**

\(^3\) a registered pharmacist under the Pharmacists Registration Act who holds a valid practising certificate and is in active practice, as defined in regulation 2 of the Pharmacists Registration (Practising Certificates) Regulations 2008 (G.N. No. S 438/2008).
efficacy and safety, and that the clinicians are fully responsible for the use of such unregistered products in their patients.

The overall requirements are summarized in the table below:

<table>
<thead>
<tr>
<th>Importer</th>
<th>Importer’s Licence</th>
<th>Wholesaler’s Licence</th>
<th>Consignment Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Licensed hospital or clinic</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Licensed retail pharmacy</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Company importing on behalf of a</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>licensed hospital or clinic</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

To submit an application for consignment approval to import and supply an unregistered therapeutic product for patient’s use, please complete the online application form or scan the QR code for the application form).

QR code for the online application form

Applicants will require CorpPass to login and access the online application form.

Please refer to Annex A on Guidance Notes for the Submission of the Online Application form, and Annex B on Frequently Asked Questions (FAQs) on the Online Application Form.
2.3 Labelling Requirements

The package or container of any therapeutic product imported through the special access route must be labelled with all of the following information:

a) the proprietary name of the therapeutic product
b) the name and appropriate quantitative particulars of any active ingredient of the therapeutic product;
c) an appropriate control number, such as a serial number, batch number or lot number;
d) the expiry date of the therapeutic product;
e) where the therapeutic product contains any of the following substances, viz. tartrazine, benzoic acid or sodium benzoate, the therapeutic product must be labelled with a statement declaring the presence of that substance.

All information must be legible, indelible and written in English.

Any unregistered therapeutic product supplied to a hospital or a clinic must be accompanied by the package insert (PI) or product information. If the original PI accompanying the product is not written in English, an English-translated PI must be provided for each supply of the unregistered therapeutic product.

Any re-labelling of the product information for the purpose of fulfilling the requirements as described in this section can be carried out by the importing company without a Manufacturer’s Licence.

2.4 Requirement for Other Licences/Approval for Specific Products

If the unregistered therapeutic product contains a controlled drug or a psychotropic substance, the following requirements will also apply:
a) A Licence to Import Controlled Drugs under the Misuse of Drugs Regulations (click here or scan the QR code to apply).

QR code for the application of licence to import controlled drug

b) Approval to import therapeutic products containing psychotropic substances (click here or scan the QR code to apply).

QR code for the application of licence to import psychotropic substances

3. TRANSFER OF UNREGISTERED THERAPEUTIC PRODUCTS BETWEEN PHMCA-LICENSED HOSPITALS OR CLINICS

A hospital or clinic may transfer an unregistered therapeutic product imported under the special access route to another hospital or clinic for the treatment of a patient treated at that hospital or clinic, without additional approval or licensing requirement.

The transferring and receiving hospitals or clinics are required to keep records of the receipt and supply as described in Section 4 below.
4. DUTIES AND OBLIGATIONS OF IMPORTERS, WHOLESALERS AND SUPPLIERS (INCLUDING HOSPITALS, CLINICS AND RETAIL PHARMACIES)

4.1 Duties to Maintain Records of Receipt and Supply

Importers, including hospitals, clinics and retail pharmacies importing under regulation 51 of the Regulations, and wholesalers of unregistered therapeutic products must maintain records of every receipt and wholesale supply of the unregistered therapeutic products, respectively. The records must be retained for at least 2 years from the date of supply, and must be made available when requested by HSA.

Records of each receipt must contain the following information:
   a) the proprietary name or description of the therapeutic product, if the therapeutic product is supplied by a manufacturer, importer or wholesaler, as the case may be;
   b) the date on which the therapeutic product is received;
   c) the name and address of the company from which the therapeutic product is received;
   d) the quantity of the therapeutic product received; and
   e) the identification number (including the control number, lot number, batch number or serial number) of the therapeutic product received.

Records of each wholesale supply must contain the following information:
   a) the proprietary name or description of the therapeutic product;
   b) the date on which the therapeutic product is supplied;
   c) the name and address of the company to which the therapeutic product is supplied;
   d) the quantity of the therapeutic product supplied; and
   e) the identification number (including the control number, lot number, batch number or serial number) of the therapeutic product supplied.
In addition, the record keeping requirements under the Misuse of Drugs Regulations must be complied with if the unregistered therapeutic product contains one or more controlled drugs, in accordance with the form of Register as prescribed in the Fifth Schedule of the Regulations. The Register must be retained for at least 3 years from the date of which the last entry is made.

**4.2 Duties to Maintain Records of Defects and Adverse effects**

Importers, including hospitals, clinics and retail pharmacies importing under regulation 51 of the Regulations, of unregistered therapeutic products must maintain records of any defect or any adverse effect arising from the use of the therapeutic product. The records must be retained for at least 2 years after the expiry date of the therapeutic product and be made available when required by HSA.

The records must contain the following information:

a) the proprietary name or description of the therapeutic product;

b) the date on which the importer first became aware of the event or occurrence;

c) the identification number (including the control number, lot number, batch number or serial number) of the therapeutic product; and

d) the nature of the defect or adverse effect.

**4.3 Duties to Report Defects and Serious Adverse Reactions**

Importers, including hospitals, clinics and retail pharmacies importing under regulation 51 of the Regulations, and wholesalers of unregistered therapeutic products must report any defect or any serious adverse reactions arising from the use of the unregistered therapeutic product to HSA.

Any defects representing a serious threat to persons or public health must be reported to HSA within 48 hours of becoming aware of the defect. In all other cases, the defect must be reported within 15 calendar days.
Any serious adverse reactions arising from the use of the unregistered therapeutic product must be reported to HSA as soon as possible within 15 calendar days.

Please also refer to the Guidance for Industry - Reporting and Recall of Defective Therapeutic Products for details on reporting of product defects to HSA, and to the Guidance for Industry – Post-marketing Vigilance Requirements for Therapeutic Products.

4.4 Duties to Notify HSA Concerning Recall

Importers, including hospitals, clinics and retail pharmacies importing under regulation 51 of the Regulations, and wholesalers who intend to recall an unregistered therapeutic product must notify HSA of the intended recall as soon as possible within 24 hours before initiating the recall.

Please also refer to the Guidance for Industry - Reporting and Recall of Defective Therapeutic Products.
ANNEX A

Guidance Notes on the Submission of the Online Application Form for Importation of a Consignment of Unregistered Therapeutic Product for Patients’ Use

1. The online application form (Sections A to E) must be completed by the applicant who is the person importing the unregistered therapeutic product.

2. Each application is specific to a single product. The doctor, dentist, pharmacist or the healthcare institution who is requesting for the unregistered therapeutic product is referred to as the Requester.

3. Up to 2 requests for the same application type (Named-Patient or Buffer Stock) and for the same product can be submitted in one application. Each application must be accompanied by the respective Signed Request(s) for the relevant application type which are completed and signed by each Requester. The Requester is required to sign a declaration that he or she assumes full responsibility for the use of the unregistered therapeutic product on the patient (click here or scan the QR code for the Signed Request form for Named-Patient Application Type and the Signed Request for Buffer-Stock Application Type).

QR code for the Signed Request form
4. The application type is determined by the purpose of the request as follows:

<table>
<thead>
<tr>
<th>Type of application</th>
<th>Purpose of the request</th>
</tr>
</thead>
</table>
| **Named-Patient application**| (a) To import and supply an unregistered therapeutic product which presents a life-saving treatment option to the patient whose condition would be clinically compromised without the requested therapy, and that there is no effective alternative therapy registered in Singapore.  

OR

(b) To import and supply a novel unregistered therapeutic product which offers a substantive clinical advantage over registered therapies and is expected to provide significant improvement in the patient’s clinical outcome.  

*Important note:*

*The application must be accompanied by the clinical justification(s) of unmet medical needs and reasons for not using current registered therapeutic products.*

| Buffer Stock application      | To import and supply the unregistered therapeutic product which is a standard essential medicine, to be kept as stocks in hospitals or clinics to meet the critical needs of Singapore’s healthcare system.  

*Important note:*

*Only medicines listed on the MOH Standard Drugs List (SDL) or the Hospital Pharmacy and...*
The applicant must ensure that the purpose of request as indicated by the Requester in the Signed Request, is correctly selected when making the application.

5. For medicines which are on both the MOH SDL and the Hospital P&T List, the MOH SDL option should be selected.

6. For an unregistered product which is imported by the applicant for the first time, the application must be accompanied by the outer and inner labels as well as package insert of the product.

7. The target processing timeline is 14 working days from the date of receipt of the application, excluding stop-clock time. The stop-clock time starts when HSA requests for clarification or additional information, and ends upon receipt of a satisfactory response.
ANNEX B

Frequently Asked Questions (FAQs) on the Online Application Form

Q1: Can I still submit an application via fax using the current PDF application form?

A: To allow sufficient time for applicants to transit from hardcopy to electronic submission, there is a 4-month transition period from 2 September 2019 to 31 January 2020. During this period, fax will remain available and will cease on 1 February 2020. Applicants are strongly encouraged to switch to the online submission during the transition period.

Q2: Why can’t I see the application form at the link provided?

A: Applicants have to login via CorpPass to access the online application form. For more information on CorpPass or to register for a CorpPass account, please click here.

Q3: If I am importing a product on behalf of a Requester (e.g. doctor), does the Requester need to log in via CorpPass to submit the application too?

A: The Requester is not required to log in via CorpPass to access the application. However, you must obtain the Requester’s Signed Request for the relevant application type before submitting the online application (click here or scan the QR code to download the Signed Request form form for Named-Patient Application Type and the Signed Request for Buffer-Stock Application Type for).

QR code for the Signed Request form
Q4: How will I know if my online application is received by TPB?

A: You will receive an email acknowledgment containing the application details and a unique reference number upon successful submission of your application. The unique reference number would serve to be the application number.

The unique reference number is a 24 alpha-numeric character, e.g. “Ref: 5d42d72a2779ec00138908c1”

For future correspondences with HSA regarding your application, please quote this application number.

Q5: Can I make changes to the application form after the submission?

A: Changes cannot be made to the application form once submitted. If you have made errors in your submission, you can withdraw the application and re-submit using a new application. To withdraw your application, please notify us at HSA_TP_SAR@hsa.gov.sg and quote the application number.

Q6: Is there a limit to the file size of the attachments?

A: You may attach files up to the maximum size up to 3 MB as specified in the respective fields in the application form. If you wish to submit multiple files, it is recommended to compress them into a zip folder prior to uploading.

Q7: How do I know if my application is approved?

A: You will be notified of the outcome of your application via email (sent to the applicant email address). For approved applications, the application number would also serve as your consignment approval number.
If the Requester would also like to be notified of the outcome of the application, please include the Requester's email address under the field "Hospital's or Clinic's Contact Email".

For enquiries, please contact us at: HSA_TP_SAR@hsa.gov.sg.